Nothing Special   »   [go: up one dir, main page]

PL2440575T3 - Identyfikacja, optymalizacja i stosowanie wspólnych epitopów hla-b*0702 do immunoterapii - Google Patents

Identyfikacja, optymalizacja i stosowanie wspólnych epitopów hla-b*0702 do immunoterapii

Info

Publication number
PL2440575T3
PL2440575T3 PL09786052T PL09786052T PL2440575T3 PL 2440575 T3 PL2440575 T3 PL 2440575T3 PL 09786052 T PL09786052 T PL 09786052T PL 09786052 T PL09786052 T PL 09786052T PL 2440575 T3 PL2440575 T3 PL 2440575T3
Authority
PL
Poland
Prior art keywords
immunotherapy
epitopes
optimization
identification
shared hla
Prior art date
Application number
PL09786052T
Other languages
English (en)
Inventor
Kostantinos Kosmatopoulos (Kostas)
Jeanne Menez-Jamet
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Publication of PL2440575T3 publication Critical patent/PL2440575T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05D—SYSTEMS FOR CONTROLLING OR REGULATING NON-ELECTRIC VARIABLES
    • G05D16/00—Control of fluid pressure
    • G05D16/20—Control of fluid pressure characterised by the use of electric means
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/02—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using elements whose operation depends upon chemical change
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Fluid Mechanics (AREA)
  • Automation & Control Theory (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09786052T 2009-06-09 2009-06-09 Identyfikacja, optymalizacja i stosowanie wspólnych epitopów hla-b*0702 do immunoterapii PL2440575T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09786052.2A EP2440575B1 (en) 2009-06-09 2009-06-09 Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy
PCT/IB2009/006332 WO2010143010A1 (en) 2009-06-09 2009-06-09 Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy

Publications (1)

Publication Number Publication Date
PL2440575T3 true PL2440575T3 (pl) 2015-04-30

Family

ID=41319617

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09786052T PL2440575T3 (pl) 2009-06-09 2009-06-09 Identyfikacja, optymalizacja i stosowanie wspólnych epitopów hla-b*0702 do immunoterapii

Country Status (11)

Country Link
US (1) US10024868B2 (pl)
EP (1) EP2440575B1 (pl)
JP (1) JP2012529283A (pl)
CN (1) CN102459322B (pl)
BR (1) BRPI0924556A2 (pl)
CA (1) CA2764760C (pl)
ES (1) ES2533228T3 (pl)
HK (1) HK1169424A1 (pl)
PL (1) PL2440575T3 (pl)
PT (1) PT2440575E (pl)
WO (1) WO2010143010A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898126A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
EP2977059A1 (en) * 2014-07-22 2016-01-27 Vaxon Biotech Immunogenic polypeptide composed of HLA-B7 restricted tumor antigen-derived optimized cryptic peptides, and uses thereof
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
KR20190059874A (ko) * 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2024138753A1 (zh) * 2022-12-30 2024-07-04 深圳吉诺因生物科技有限公司 一种hla-a*24:02限制性抗原点替换方法、获得的多肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
AU7440196A (en) * 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
AU2085001A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
FR2837837B1 (fr) 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
CN100418981C (zh) * 2002-06-10 2008-09-17 瓦西尼斯公司 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
US7698688B2 (en) * 2008-03-28 2010-04-13 International Business Machines Corporation Method for automating an internationalization test in a multilingual web application
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Also Published As

Publication number Publication date
CN102459322A (zh) 2012-05-16
US20120142894A1 (en) 2012-06-07
BRPI0924556A2 (pt) 2015-06-30
ES2533228T3 (es) 2015-04-08
US10024868B2 (en) 2018-07-17
EP2440575A1 (en) 2012-04-18
CA2764760A1 (en) 2010-12-16
CA2764760C (en) 2019-11-26
CN102459322B (zh) 2015-11-25
HK1169424A1 (en) 2013-01-25
WO2010143010A1 (en) 2010-12-16
JP2012529283A (ja) 2012-11-22
EP2440575B1 (en) 2014-11-05
PT2440575E (pt) 2015-02-12

Similar Documents

Publication Publication Date Title
PT2440575E (pt) Identificação, optimização e utilização de epitopos hla-b*0702 partilhados para imunoterapia
PL2413956T3 (pl) Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii
HK1177752A1 (en) Anti-c5a antibodies and methods for using the antibodies -c5a
EP2481752A4 (en) MODIFIED CONSTANT ANTIBODY REGIONS
EP2762488A4 (en) PEPTIDE FOR SYNTHESIS OF SILICA AND USE THEREOF
IL214956A0 (en) Antibody formulation
IL219537A0 (en) Antibody formulation
IL225667A0 (en) A new antigen
SI2946791T1 (sl) Protitelesa proti CD277 in uporabe le-teh
IL225514A (en) Personal Jewel
HK1179981A1 (zh) 的抗體及其用途
IL226106A0 (en) Methods and preparations for immunotherapy in neurological diseases
IL225579A0 (en) Glycoforms of an antibody against the alpha-folate receptor
HK1162538A1 (en) Novel anti-51 antibodies and uses thereof -51
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
HK1170745A1 (en) Antibodies against il-17br il-17br
EP2481755A4 (en) ANTIBODY CAPABLE OF RECOGNIZING CLASS I HLA
GB0903151D0 (en) Antibody uses and methods
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
EP2602770A4 (en) IDENTIFICATION PAPER
IL202423A0 (en) Sleeve for holding and identification